Vascular cell adhesion molecule 1 (VCAM-1) and Integrin alpha-4 beta-1 (VLA-4) (VCAM-1/VLA-4)

The Vascular cell adhesion molecule 1 (VCAM-1) and Integrin alpha-4 beta-1 (VLA-4) axis is a critical molecular interaction governing leukocyte recruitment and inflammatory signaling. VCAM-1 (CD106) is a transmembrane glycoprotein primarily expressed on cytokine-activated vascular endothelial cells, while its ligand, VLA-4 (composed of ITGA4 and ITGB1), is expressed on the surface of most leukocytes (UniProt P19320, P13612). This interaction facilitates the firm adhesion of leukocytes to the vessel wall and their subsequent migration into tissues, a process central to the pathogenesis of various inflammatory and autoimmune diseases. In the myocardium, VCAM-1 expression is markedly increased following ischemic injury, driving the infiltration of monocytes and T-cells that contribute to post-infarct remodeling and potential heart failure (PubMed: 30249714). Additionally, this axis has been implicated in lymphatic signaling, where it regulates the trafficking of immune cells through lymphatic vessels and may influence lymphangiogenesis in response to cardiac injury (PubMed: 32814556). Therapeutic targeting of this pathway, most notably with the monoclonal antibody natalizumab, has proven effective in treating multiple sclerosis and Crohn's disease by blocking leukocyte entry into the central nervous system and gastrointestinal tract (FDA: Tysabri Label). However, the use of such inhibitors is associated with significant safety concerns, particularly the risk of progressive multifocal leukoencephalopathy (PML) due to suppressed immune surveillance.

Other names

CD106Very Late Antigen-4Integrin alpha-4 beta-1ITGA4/ITGB1CD49d/CD29INCAM-100

Antagonism of the VLA-4 integrin receptor to prevent its binding to VCAM-1, thereby inhibiting leukocyte adhesion and transmigration into inflamed tissues.